Harbour BioMed Names Vivian Feng Head of External Collaboration
Biopharmaceutical company Harbour BioMed has appointed Vivian Feng to oversee external collaborations, aiming to strengthen its strategic partnership network for antibody therapeutic development.
Harbour BioMed (HKEX: 02142) has appointed Vivian Feng as its new Head of External Collaboration. Feng will lead the company’s efforts to build and maintain strategic partnerships aimed at advancing its portfolio of novel antibody therapeutics.
The appointment comes as the biopharmaceutical sector increasingly relies on collaboration to expedite drug development in complex fields such as immunology and oncology. Feng is expected to focus on integrating external research initiatives into the company's existing development framework.
Harbour BioMed operates globally, with research and operational hubs located in Shanghai, Rotterdam, and Cambridge, Massachusetts.